Last reviewed · How we verify
NCT04393558
Wearable Sensor to Monitor COVID-19 Like Signs and Symptoms
trial testing ADAM Sensor in COVID-19 in 75 participants. Completed in 26 October 2020.
26 October 2020
Quick facts
| Lead sponsor | Shirley Ryan AbilityLab |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 75 |
| Start date | 20 April 2020 |
| Primary completion | 26 October 2020 |
| Estimated completion | 26 October 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- ADAM Sensor
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- Healthy Control — all drugs for Healthy Control →
Sponsor
Shirley Ryan AbilityLab — full company profile →
Who can join
Adults 18 to 95, any sex, with COVID-19 or Healthy Control. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
1. Develop a wearable sensor package to gather data on COVID-19-like signs and symptoms such as elevated body temperature, respiratory parameters, heart rate ,cough and gait. 2. Create algorithms to monitor and track changes to COVID19-like signs and symptoms for developing a better care and isolation strategies for COVID-19 pandemic.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04393558
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Shirley Ryan AbilityLab trials
Trials by the same sponsor.
- NCT07434492 — Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy · Phase 2 · not yet recruiting
- NCT07433023 — tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy · Phase 2 · not yet recruiting
- NCT06999213 — Lower Limb ExoNET: Development and Evaluation for Gait Assistance With Stroke Survivors · EARLY_PHASE1 · not yet recruiting
- NCT07032753 — Neuromusculoskeletal Interface for Bionic Arms · NA · not yet recruiting
- NCT07223710 — Improving Walking After Spinal Cord Injury · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04393558 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shirley Ryan AbilityLab
- Last refreshed: 17 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04393558.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing